Losing Lyumjev: how the system failed patients
As various presentations of Lyumjev are withdrawn across Europe, we take a deep dive into what lies behind the commercial reasons that Lilly has stated.
Lyumjev
Living with #Lyumjev. Almost a year in review…
Lyumjev. Still the newest insulin available and still the fastest kid on the block. But a year with it hasn’t always been the most straightforward […]
Lyumjev part 4. Persistence is king…
As some readers may have seen, I was somewhat disappointed when I first put Lyumjev into a pump and started using it with a DIYAPS […]
Lyumjev – a fully closed loop case study with oref1
When Lyumjev, or URLi was announced, and pharmacodynamic details released back in September 2019, I noted that it had the potential to transform the use […]
Clinical benefits of faster insulins – an n=1 answer to a common #EASD2020 question
Whilst watching EASD2020 this week, during the session on developing better insulins, a question was asked by multiple participants in relation to faster insulins. This […]
Lyumjev. What next? Another n=1 experiment…
Warning: What is discussed in this post is not recommended by the manufacturers and not aligned with the European Medicines Agency sign off for Lyumjev […]
Lyumjev. Ultrafast? It depends…
Lyumjev proved not to be so rapid for me when used in a pump, but when injected, met expectations. Some examples and thoughts about this.
Insulin Lyumjev… Not as URLi as I expected!
As readers of this page will be aware, I’ve been following Ultra Rapid Lispro for a little while, as Lilly has published various data at […]